Open AccessLiquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies
Author(s) -
Corinna Keup,
Rainer Kimmig,
Sabine KasimirBauer
Publication year - 2020
Publication title -
breast care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.767
H-Index - 30
eISSN - 1661-3805
pISSN - 1661-3791
DOI - 10.1159/000510509
Subject(s) - medicine , liquid biopsy , immunogenicity , immune system , biomarker , circulating tumor cell , microsatellite instability , breast cancer , immunotherapy , oncology , cancer research , biopsy , cancer , immunology , metastasis , biology , biochemistry , allele , gene , microsatellite
Despite the assumption of breast cancer (BC) as a cold, non-immunogenic tumor, immune checkpoint inhibitor (ICI) therapy is favorable for a subgroup of patients. Immunohistochemical assessment of the programmed cell death ligand 1 (PD-L1) is the only approved companion diagnostic for anti-PD-L1 therapy in metastatic triple-negative BC; however, challenges regarding the standardization of PD-L1 scoring in tumor tissue still remain. Consequently, to select patients most likely to respond to ICI, blood-based biomarkers are urgently needed.